Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
13.76
+0.04 (0.29%)
At close: Jan 16, 2026, 4:00 PM EST
13.80
+0.04 (0.32%)
After-hours: Jan 16, 2026, 7:44 PM EST
Janux Therapeutics Employees
Janux Therapeutics had 81 employees as of December 31, 2024. The number of employees increased by 17 or 26.56% compared to the previous year.
Employees
81
Change (1Y)
17
Growth (1Y)
26.56%
Revenue / Employee
$123,457
Profits / Employee
-$1,257,963
Market Cap
827.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Dec 31, 2023 | 64 | 4 | 6.67% |
| Dec 31, 2022 | 60 | 27 | 81.82% |
| Dec 31, 2021 | 33 | 21 | 175.00% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
JANX News
- 25 days ago - Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Business Wire
- 6 weeks ago - Janux Therapeutics Stock Hits 52-Week Low After Trial Update - Benzinga
- 6 weeks ago - Janux dives as gaps in prostate cancer study data worry investors - Reuters
- 6 weeks ago - Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 6 weeks ago - Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%. - Barrons
- 6 weeks ago - Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript - Seeking Alpha
- 6 weeks ago - Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC - Business Wire
- 7 weeks ago - Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC - Business Wire